420 related articles for article (PubMed ID: 32243492)
1. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
2. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
3. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
[TBL] [Abstract][Full Text] [Related]
4. Inclisiran in lipid management: A Literature overview and future perspectives.
Scicchitano P; Milo M; Mallamaci R; De Palo M; Caldarola P; Massari F; Gabrielli D; Colivicchi F; Ciccone MM
Biomed Pharmacother; 2021 Nov; 143():112227. PubMed ID: 34563953
[TBL] [Abstract][Full Text] [Related]
5. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
[TBL] [Abstract][Full Text] [Related]
6. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
7. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials.
Cupido AJ; Kastelein JJP
Cardiovasc Res; 2020 Sep; 116(11):e136-e139. PubMed ID: 32766688
[No Abstract] [Full Text] [Related]
8. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
[TBL] [Abstract][Full Text] [Related]
10. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP
JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410
[TBL] [Abstract][Full Text] [Related]
11. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
12. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M
Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005
[TBL] [Abstract][Full Text] [Related]
13. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.
Wright RS; Collins MG; Stoekenbroek RM; Robson R; Wijngaard PLJ; Landmesser U; Leiter LA; Kastelein JJP; Ray KK; Kallend D
Mayo Clin Proc; 2020 Jan; 95(1):77-89. PubMed ID: 31630870
[TBL] [Abstract][Full Text] [Related]
14. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
[TBL] [Abstract][Full Text] [Related]
15. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
[TBL] [Abstract][Full Text] [Related]
16. Inclisiran for the treatment of dyslipidemia.
Nishikido T; Ray KK
Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
[TBL] [Abstract][Full Text] [Related]
17. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
18. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
[TBL] [Abstract][Full Text] [Related]
19. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
